Interacciones de Atropina

Atropina (AtroPen, Isopto Atropine), anticolinérgico, tiene 123 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 19; moderadas: 82; leves: 20; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 2. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (19)

  • AclidinioanticolinérgicoGrave

    Avoid administrations of TUDORZA PRESSAIR with other anticholinergic-containing drugs. (etiqueta de Aclidinio, Interacciones medicamentosas)

  • AlcoholAlcoholGrave

    Benzyl Alcohol The preservative benzyl alcohol has been associated with serious adverse events and death in neonates. (etiqueta de Atropina, Advertencias y precauciones)

  • BenzatropinaanticolinérgicoGrave

    Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients. (etiqueta de Benzatropina, Contraindicaciones)

  • Citrato de potasiosuplemento de potasioGrave

    In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (etiqueta de Citrato de potasio, Contraindicaciones)

  • ClozapinaantipsicóticoGrave

    When possible, avoid concomitant use, with other anticholinergic medications because the risk for anticholinergic toxicity or severe gastrointestinal adverse reactions is increased [see Warnings and Precautions ( 5.7 ), Drug Interactions ( 7.1 )]. (etiqueta de Clozapina, Advertencias y precauciones)

  • Usage of MOTOFEN ® in recommended doses is not likely to cause prominent anticholinergic side effects, but MOTOFEN ® should be avoided in patients in whom anticholinergic drugs are contraindicated. (etiqueta de Difenoxina y atropina, Advertencias)

  • GlicopirronioanticolinérgicoGrave

    • Other Conditions Exacerbated by Anticholinergic Adverse Reactions : Use is not recommended in patients with autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia, etc. (etiqueta de Glicopirronio, Advertencias y precauciones)

  • Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

  • IpratropioanticolinérgicoGrave

    Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (etiqueta de Ipratropio, Contraindicaciones)

  • Ipratropio y salbutamolanticolinérgicoGrave

    CONTRAINDICATIONS Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. (etiqueta de Ipratropio y salbutamol, Contraindicaciones)

  • Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. (etiqueta de Irinotecán, Advertencia en recuadro)

  • Metoclopramidaantagonista de la dopaminaGrave

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. (etiqueta de Metoclopramida, Advertencias y precauciones)

  • Piridostigminainhibidor de la colinesterasaGrave

    WARNING: RISKS WITH IMPROPER USE OF PYRIDOSTIGMINE BROMIDE After Exposure to Soman, Use Atropine and Pralidoxime Pyridostigmine bromide is for use as a pretreatment for exposure to soman nerve agent. (etiqueta de Piridostigmina, Advertencia en recuadro)

  • QuinidinaantiarrítmicoGrave

    Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (etiqueta de Quinidina, Contraindicaciones)

  • Rivastigminainhibidor de la colinesterasaGrave

    Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (etiqueta de Rivastigmina, Interacciones medicamentosas)

  • TiotropioanticolinérgicoGrave

    Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (etiqueta de Tiotropio, Interacciones medicamentosas)

  • Tranilciprominainhibidor de la MAOGrave

    …(HR) b or Serotonin Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension… (etiqueta de Tranilcipromina, Interacciones medicamentosas)

  • UmeclidinioanticolinérgicoGrave

    Avoid administration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs. (etiqueta de Umeclidinio, Interacciones medicamentosas)

  • Umeclidinio y vilanterolanticolinérgicoGrave

    Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs. (etiqueta de Umeclidinio y vilanterol, Interacciones medicamentosas)

Interacciones moderadas (82)

  • AripiprazolantipsicóticoModerada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etiqueta de Aripiprazol, Advertencias y precauciones)

  • AsenapinaantipsicóticoModerada

    Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use SAPHRIS with caution in patient who may experience these conditions. (etiqueta de Asenapina, Advertencias y precauciones)

  • Benazepril e hidroclorotiazidainhibidor de la ECAModerada

    Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. (etiqueta de Benazepril e hidroclorotiazida, Interacciones medicamentosas)

  • BrexpiprazolantipsicóticoModerada

    Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (etiqueta de Brexpiprazol, Advertencias y precauciones)

  • BuprenorfinaopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Buprenorfina, Interacciones medicamentosas)

  • Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Buprenorfina y naloxona, Interacciones medicamentosas)

  • Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína, Interacciones medicamentosas)

  • Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Butalbital, paracetamol, cafeína y codeína, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoModerada

    Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etiqueta de Carbamazepina, Advertencias y precauciones)

  • CarbidopaModerada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (etiqueta de Carbidopa, Advertencias)

  • CarbinoxaminaantihistamínicoModerada

    Concomitant Medical Conditions Carbinoxamine Maleate Extended-Release Oral Suspension has anticholinergic (atropine-like) properties and, therefore, should be used with caution in patients with: increased intraocular pressure, narrow angle glaucoma, hyperthyroidism, cardiovascular disease, hypertension, stenosing peptic ulcer, symptomatic prostatic hypertrophy,… (etiqueta de Carbinoxamina, Advertencias y precauciones)

  • CariprazinaantipsicóticoModerada

    Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use VRAYLAR with caution in patient who may experience these conditions. (etiqueta de Cariprazina, Advertencias y precauciones)

  • Ciclobenzaprinarelajante muscularModerada

    Atropine-like Adverse Reactions: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure and in patients taking anticholinergic medications. (etiqueta de Ciclobenzaprina, Advertencias y precauciones)

  • ClorpromazinaantipsicóticoModerada

    Use with caution in persons who will be exposed to extreme heat, organophosphorus insecticides and in persons receiving atropine or related drugs. (etiqueta de Clorpromazina, Precauciones)

  • CodeínaopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Codeína, Interacciones medicamentosas)

  • DarifenacinaanticolinérgicoModerada

    Darifenacin extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as severe constipation, ulcerative colitis, and myasthenia gravis. (etiqueta de Darifenacina, Advertencias y precauciones)

  • Deutetrabenazinainhibidor de VMAT2Moderada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etiqueta de Deutetrabenazina, Advertencias y precauciones)

  • DexclorfeniraminaantihistamínicoModerada

    PRECAUTIONS CORPHENA Oral Solution has an atropine-like action and, therefore, should be used with caution in patients with: History of bronchial asthma Increased intraocular pressure Hyperthyroidism Cardiovascular disease Hypertension Drug Interaction MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines. (etiqueta de Dexclorfeniramina, Precauciones)

  • Dexmedetomidinaagonista alfa-adrenérgicoModerada

    The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. (etiqueta de Dexmedetomidina, Advertencias y precauciones)

  • Dextrometorfano y quinidinafármaco serotoninérgicoModerada

    Anticholinergic effects of quinidine: Monitor for worsening in myasthenia gravis and other sensitive conditions. (etiqueta de Dextrometorfano y quinidina, Advertencias y precauciones)

  • DicicloverinaanticolinérgicoModerada

    Anticholinergic agents: may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs (7) (etiqueta de Dicicloverina, Interacciones medicamentosas)

  • Clinical presentations vary in terms of which toxicity (anticholinergic vs. opioid) will present first or predominate; non-specific findings have been reported and include symptoms such as drowsiness (see OVERDOSAGE ). (etiqueta de Difenoxilato y atropina, Advertencias)

  • DronabinolcannabinoideModerada

    Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (etiqueta de Dronabinol, Advertencias y precauciones)

  • EluxadolinaopioideModerada

    Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (etiqueta de Eluxadolina, Interacciones medicamentosas)

  • EscopolaminaanticolinérgicoModerada

    • Gastrointestinal and Urinary Disorders : Consider more frequent monitoring during treatment in patients suspected of having intestinal obstruction; patients with pyloric obstruction, patients with impeded urine flow or receiving other anticholinergic drugs. (etiqueta de Escopolamina, Advertencias y precauciones)

  • FenilefrinadescongestionanteModerada

    Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (etiqueta de Fenilefrina, Interacciones medicamentosas)

  • FentaniloopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Fentanilo, Interacciones medicamentosas)

  • FesoterodinaanticolinérgicoModerada

    Urinary Retention in Adult Patients With Bladder Outlet Obstruction The use of Toviaz, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction, including patients with urinary retention, may result in further urinary retention and kidney injury. (etiqueta de Fesoterodina, Advertencias y precauciones)

  • FlufenazinaantipsicóticoModerada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Flufenazina, Advertencias)

  • HaloperidolantipsicóticoModerada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Haloperidol, Advertencias)

  • HidrocodonaopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Hidrocodona, Interacciones medicamentosas)

  • Anticholinergics The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Hidrocodona e ibuprofeno, Interacciones medicamentosas)

  • Anticholinergic Drugs The concomitant use of anticholinergic drugs with hydrocodone bitartrate and homatropine methylbromide may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus [see Warnings and Precautions (5.9) ] . (etiqueta de Hidrocodona y homatropina, Interacciones medicamentosas)

  • Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Hidrocodona y paracetamol, Interacciones medicamentosas)

  • HidromorfonaopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Hidromorfona, Interacciones medicamentosas)

  • IloperidonaantipsicóticoModerada

    Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use FANAPT with caution in patients who may experience these conditions. (etiqueta de Iloperidona, Advertencias y precauciones)

  • LevorfanolopioideModerada

    Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Levorfanol, Interacciones medicamentosas)

  • LoxapinaantipsicóticoModerada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (etiqueta de Loxapina, Advertencias)

  • MetadonaopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Metadona, Interacciones medicamentosas)

  • MexiletinaantiarrítmicoModerada

    Mexiletine : Decreases rate of mexiletine absorption. (etiqueta de Atropina, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoModerada

    • Urinary Retention in Patients With Bladder Outlet Obstruction and in Patients Taking Muscarinic Antagonist Drugs for Overactive Bladder : Administer with caution in these patients because of risk of urinary retention. (etiqueta de Mirabegrón, Advertencias y precauciones)

  • MorfinaopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Morfina, Interacciones medicamentosas)

  • NalbufinaopioideModerada

    Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Nalbufina, Interacciones medicamentosas)

  • Neostigminainhibidor de la colinesterasaModerada

    Bradycardia : Atropine or glycopyrrolate should be administered prior to administration of neostigmine methylsulfate injection to lessen risk of bradycardia ( 5.1 ) (etiqueta de Neostigmina, Advertencias y precauciones)

  • Nortriptilinaantidepresivo tricíclicoModerada

    Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (etiqueta de Nortriptilina, Interacciones medicamentosas)

  • OlanzapinaantipsicóticoModerada

    Anticholinergic (antimuscarinic) Effects: Use with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, constipation, paralytic ileus or related conditions. (etiqueta de Olanzapina, Advertencias y precauciones)

  • Olanzapina y fluoxetinaantipsicóticoModerada

    Anticholinergic (antimuscarinic) Effects : Use with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, constipation, history of paralytic ileus or related conditions ( 5.21 ) (etiqueta de Olanzapina y fluoxetina, Advertencias y precauciones)

  • OliceridinaopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Oliceridina, Interacciones medicamentosas)

  • OxibutininaanticolinérgicoModerada

    Oxybutynin chloride extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony. (etiqueta de Oxibutinina, Advertencias y precauciones)

  • OxicodonaopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Oxicodona, Interacciones medicamentosas)

  • Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Oxicodona y paracetamol, Interacciones medicamentosas)

  • OximorfonaopioideModerada

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Oximorfona, Interacciones medicamentosas)

  • Paracetamol y codeínaopioideModerada

    Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Paracetamol y codeína, Interacciones medicamentosas)

  • Pentazocina y naloxonaopioideModerada

    Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Pentazocina y naloxona, Interacciones medicamentosas)

  • PerfenazinaantipsicóticoModerada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Perfenazina, Advertencias)

  • Petidina (meperidina)opioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Petidina (meperidina), Interacciones medicamentosas)

  • Pilocarpinaagonista colinérgicoModerada

    These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (etiqueta de Pilocarpina, Interacciones medicamentosas)

  • PimozidaantipsicóticoModerada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Pimozida, Advertencias)

  • ProcainamidaantiarrítmicoModerada

    Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (etiqueta de Procainamida, Interacciones medicamentosas)

  • Propofoldepresor del SNCModerada

    The intravenous administration of anticholinergic agents (e.g., atropine or glycopyrrolate) should be considered to modify potential increases in vagal tone due to concomitant agents (e.g., succinylcholine) or surgical stimuli. (etiqueta de Propofol, Advertencias y precauciones)

  • QuetiapinaantipsicóticoModerada

    • Anticholinergic (antimuscarinic) Effects: Use with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, or constipation (5.20) (etiqueta de Quetiapina, Advertencias y precauciones)

  • Sevofluranoanestésico generalModerada

    Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (etiqueta de Sevoflurano, Advertencias)

  • SolifenacinaanticolinérgicoModerada

    Urinary Retention The use of Solifenacin succinate tablets, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction including patients with urinary retention, may result in further urinary retention and kidney injury. (etiqueta de Solifenacina, Advertencias y precauciones)

  • SugammadexModerada

    Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (etiqueta de Sugammadex, Advertencias y precauciones)

  • Suxametonio (succinilcolina)bloqueador neuromuscularModerada

    Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (etiqueta de Suxametonio (succinilcolina), Advertencias y precauciones)

  • TapentadolopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Tapentadol, Interacciones medicamentosas)

  • Tetrabenazinainhibidor de VMAT2Moderada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etiqueta de Tetrabenazina, Advertencias y precauciones)

  • TiotixenoantipsicóticoModerada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Tiotixeno, Advertencias)

  • TopiramatoanticonvulsivoModerada

    Caution should be used when topiramate extended-release capsules are prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity. (etiqueta de Topiramato, Advertencias y precauciones)

  • Toxina botulínica tipo Abloqueador neuromuscularModerada

    Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (etiqueta de Toxina botulínica tipo A, Interacciones medicamentosas)

  • Toxina incobotulínica Abloqueador neuromuscularModerada

    Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (etiqueta de Toxina incobotulínica A, Advertencias y precauciones)

  • Toxina onabotulínica Abloqueador neuromuscularModerada

    Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (etiqueta de Toxina onabotulínica A, Interacciones medicamentosas)

  • TramadolopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Tramadol, Interacciones medicamentosas)

  • Tramadol y paracetamolopioideModerada

    Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (etiqueta de Tramadol y paracetamol, Interacciones medicamentosas)

  • TrifluoperazinaantipsicóticoModerada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (etiqueta de Trifluoperazina, Advertencias)

  • TrihexifenidiloanticolinérgicoModerada

    Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (etiqueta de Trihexifenidilo, Advertencias)

  • The recent use of other drugs that cause CNS depression or EPS symptoms (e.g., alcohol, sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics) may also increase the risk for these serious CNS reactions [see Warnings and Precautions ( 5.1 , 5.5 )] . (etiqueta de Trimetobenzamida, Advertencias y precauciones)

  • TrospioanticolinérgicoModerada

    Trospium chloride extended-release capsules, like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis. (etiqueta de Trospio, Advertencias y precauciones)

  • Valbenazinainhibidor de VMAT2Moderada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etiqueta de Valbenazina, Advertencias y precauciones)

  • Vibegrónagonista beta-adrenérgicoModerada

    Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater. (etiqueta de Vibegrón, Advertencias y precauciones)

  • ZiprasidonaantipsicóticoModerada

    Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (etiqueta de Ziprasidona, Advertencias y precauciones)

  • ZonisamidaanticonvulsivoModerada

    Caution should be used when ZONISADE is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, carbonic anhydrase inhibitors and drugs with anticholinergic activity. (etiqueta de Zonisamida, Advertencias y precauciones)

Menciones leves (20)

  • Cevimelinaagonista colinérgicoLeve

    Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (etiqueta de Cevimelina, Interacciones medicamentosas)

  • ClonazepambenzodiazepinaLeve

    In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the C max of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to… (etiqueta de Clonazepam, Interacciones medicamentosas)

  • Clonidinaagonista alfa-adrenérgicoLeve

    There have been post-marketing reports of patients with conduction abnormalities and/or taking other sympatholytic drugs who developed severe bradycardia requiring intravenous (IV) atropine, IV isoproterenol, and temporary cardiac pacing while taking clonidine. (etiqueta de Clonidina, Advertencias y precauciones)

  • Clordiazepóxido y clidiniobenzodiazepinaLeve

    As with other anticholinergic drugs, clidinium may cause suppression of lactation. (etiqueta de Clordiazepóxido y clidinio, Interacciones medicamentosas)

  • DobutaminasimpaticomiméticoLeve

    Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (etiqueta de Dobutamina, Interacciones medicamentosas)

  • Donepeziloinhibidor de la colinesterasaLeve

    Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etiqueta de Donepezilo, Interacciones medicamentosas)

  • EfedrinasimpaticomiméticoLeve

    Clonidine, propofol, monoamine oxidase inhibitors (MAOIs), atropine C linical Impact: These drugs augment the pressor effect of ephedrine. (etiqueta de Efedrina, Interacciones medicamentosas)

  • FingolimodinmunosupresorLeve

    The conduction abnormalities were usually transient and asymptomatic, and resolved within the first 24 hours on treatment, but they occasionally required treatment with atropine or isoproterenol. (etiqueta de Fingolimod, Advertencias y precauciones)

  • FlumazenilobenzodiazepinaLeve

    Flumazenil is not recommended in cases of serious cyclic antidepressant poisoning, as manifested by motor abnormalities (twitching, rigidity, focal seizure), dysrhythmia (wide QRS, ventricular dysrhythmia, heart block), anticholinergic signs (mydriasis, dry mucosa, hypoperistalsis), and cardiovascular collapse at presentation. (etiqueta de Flumazenilo, Advertencias)

  • Galantaminainhibidor de la colinesterasaLeve

    Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etiqueta de Galantamina, Interacciones medicamentosas)

  • Imipraminaantidepresivo tricíclicoLeve

    In occasional susceptible patients or in those receiving anticholinergic drugs (including antiparkinsonism agents) in addition, the atropine-like effects may become more pronounced (e.g., paralytic ileus). (etiqueta de Imipramina, Interacciones medicamentosas)

  • LumateperonaantipsicóticoLeve

    Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (etiqueta de Lumateperona, Advertencias y precauciones)

  • LurasidonaantipsicóticoLeve

    Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. (etiqueta de Lurasidona, Advertencias y precauciones)

  • Memantina y donepeziloinhibidor de la colinesterasaLeve

    NAMZARIC may interfere with anticholinergic medications. (etiqueta de Memantina y donepezilo, Interacciones medicamentosas)

  • MidazolambenzodiazepinaLeve

    Other Drugs Used in the Surgical Setting No significant adverse interactions with commonly used premedications or drugs used during anesthesia and surgery (including atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, d-tubocurarine, succinylcholine and other nondepolarizing muscle relaxants) or topical local anesthetics (including lidocaine, dyclonine… (etiqueta de Midazolam, Interacciones medicamentosas)

  • PaliperidonaantipsicóticoLeve

    Appropriate care is advised when prescribing ERZOFRI to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. (etiqueta de Paliperidona, Advertencias y precauciones)

  • RemifentaniloopioideLeve

    It is responsive to ephedrine or anticholinergic drugs ( 5.8 ) (etiqueta de Remifentanilo, Advertencias y precauciones)

  • TioridazinaantipsicóticoLeve

    Attention should be paid to the fact that phenothiazines are capable of potentiating central nervous system depressants (e.g., anesthetics, opiates, alcohol, etc.) as well as atropine and phosphorus insecticides. (etiqueta de Tioridazina, Advertencias)

  • It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (etiqueta de Tolcapona, Precauciones)

  • Trimipraminaantidepresivo tricíclicoLeve

    Similarly, atropine-like effects may be more pronounced in patients receiving anticholinergic therapy. (etiqueta de Trimipramina, Interacciones medicamentosas)

Sin interacción significativa según la etiqueta (2)

  • HidroxizinaantihistamínicoSin interacción

    Atropine and other belladonna alkaloids are not affected by the drug. (etiqueta de Hidroxizina, Precauciones)

  • Ropinirolagonista de la dopaminaSin interacción

    Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (etiqueta de Ropinirol, Interacciones medicamentosas)

Compruebe Atropina frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.